Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review
International Journal of Molecular Sciences · 11.07.2023 · 24 (14) · 11299
DOI: 10.3390/ijms241411299 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 11.07.2023. Verfasst von Charitomeni Gioukaki und 6 weiteren Autor:innen. Beteiligte Einrichtung: First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Serine Endopeptidases, p300-CBP Transcription Factors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 122 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Prostate cancer is one of the most common malignant diseases in men, and it contributes significantly to the increased mortality rate in men worldwide. This study aimed to review the roles of p300 and TMPRSS2 (transmembrane protease, serine 2) in the AR (androgen receptor) pathway as they are closely related to the development and progression of prostate cancer. This paper represents a library-based study conducted by selecting the most suitable, up-to-date scientific published articles from online journals. We focused on articles that use similar techniques, particularly those that use prostate cancer cell lines and immunohistochemical staining to study the molecular impact of p300 and TMPRSS2 in prostate cancer specimens. The TMPRSS2:ERG fusion is considered relevant to prostate cancer, but its association with the development and progression as well as its clinical significance have not been fully elucidated. On the other hand, high p300 levels in prostate cancer biopsies predict larger tumor volumes, extraprostatic extension of disease, and seminal vesicle involvement at prostatectomy, and may be associated with prostate cancer progression after surgery. The inhibition of p300 has been shown to reduce the proliferation of prostate cancer cells with TMPRSS2:ETS (E26 transformation-specific) fusions, and combining p300 inhibitors with other targeted therapies may increase their efficacy. Overall, the interplay between the p300 and TMPRSS2 pathways is an active area of research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.
- Department of Clinical Biochemistry, Attikon University Hospital, National and Kapodistrian University of Athens, 12461 Athens, Greece.
- 1st Urology Department, Laiko Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
- Cytopathology Department, Attikon University Hospital, National and Kapodistrian University of Athens, 12461 Athens, Greece.
ORCID-Profile: Christos Kroupis, Andreas C Lazaris
Zitieren
APA
Gioukaki, C., Georgiou, A., Gkaralea, L. E., Kroupis, C., Lazaris, A. C., Alamanis, C., & Thomopoulou, G. E. (2023). Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review. International Journal of Molecular Sciences, 24(14), 11299. https://doi.org/10.3390/ijms241411299
Vancouver
Gioukaki C, Georgiou A, Gkaralea LE, Kroupis C, Lazaris AC, Alamanis C, et al. Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review. International Journal of Molecular Sciences. 2023;24(14):11299. doi:10.3390/ijms241411299
BibTeX
@article{Gioukaki2023,
author = {Gioukaki, Charitomeni and Georgiou, Alexandros and Gkaralea, Lydia Evangelia and Kroupis, Christos and Lazaris, Andreas C and Alamanis, Christos and Thomopoulou, Georgia Eleni},
title = {Unravelling the Role of P300 and TMPRSS2 in Prostate Cancer: A Literature Review},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {14},
pages = {11299},
doi = {10.3390/ijms241411299}
}
EUVIMED